High Dose Intravitreal Ranibizumab for Recalcitrant Radiation Retinopathy
NCT01334879
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
10
Enrollment
OTHER
Sponsor class
Conditions
Radiation Retinopathy
Interventions
DRUG:
ranibizumab 2.0 mg
Sponsor
The New York Eye Cancer Center
Collaborators
[object Object]